colistin


Also found in: Medical, Encyclopedia, Wikipedia.
Related to colistin: Colistin sulfate

co·lis·tin

 (kə-lĭs′tĭn, kō-)
n.
An antibiotic produced by the bacterium Bacillus polymyxa (also known as B. colistinus) that is effective against a wide range of gram-negative bacteria and is used in the treatment of certain infections, especially of the ear.

[From New Latin colistīnus, specific epithet, from coli-.]

colistin

(kəˈlɪstɪn)
n
(Medicine) a polymyxin antibiotic

co•lis•tin

(kəˈlɪs tɪn)

n.
a broad-spectrum antibiotic derived from the soil bacterium Bacillus colistinus, used esp. for treating gastroenteritis.
[1950–55; < New Latin colistinus epithet for a variety of Bacillus polymyxa]
References in periodicals archive ?
Ashton et al., "Detection of the plasmid-mediated mcr-1 gene conferring colistin resistance in human and food isolates of Salmonella enterica and Escherichia coli in England and Wales," Journal of Antimicrobial Chemotherapy, vol.
In order to deal with such situation Tigecycline, polymyxins (colistin and polymyxinB) and Fosfomycin are considered possible candidate therapies for infections caused by CPE.
[2] This trend correlates with the mounting rates of MDR and extensively drug-resistant (XDR) Gram-negative pathogens, which include the carbapenemase-producing Enterobacteriaceae (CPE), which often require the use of older, more toxic drugs such as colistin as last-resort salvage therapy for critically ill patients in hospital settings.
The discounter came bottom in a league table published by the Alliance (ASOA) this week, which measured the efforts of the UK's biggest supermarkets on a list of seven criteria: readily available policy; restrictions on antibiotics deemed critically important to human health (CIAs); monitoring usage; bans on colistin; bans on routine use of antibiotoics; publication of usage data; and reduction strategies in place.
The following antimicrobial groups according to the Anatomical Therapeutic Chemical classification (12) were analysed; J01CR05 and J01CR01 (combination ofpenicillins, including combinations of the beta-lactamase inhibitor; piperacillin/tazobactam and ampicillin/sulbactamA J01DD (thirdgeneration cephalosporins; ceftriaxone and ceftazidime), J01DH (carbapenems; meropenem and imipenem), J01GB (aminoglycosides; gentamicin and amikacin), J01MA (fluoroquinolones; ciprofloxacin and levofloxacin), J01AA12 (tigecycline) and J01XB01 (colistin).
morganii (Mm-141, and Mm-234) exhibited an extreme level of resistance against [beta]-lactam and non [beta]-lactam classes of antimicrobials, whereas out of 23 antibiotics Enterobacter cloacae (Ec-93 and Ec-188) were sensitive to tigecycline and Citrobacter freundii (Cf-276) to polymyxin-B, tigecycline and colistin only.
The growing epidemic of infections in the ICU caused by MDR pathogens has led clinicians to reconsider prescribing pPB and colistin (polymyxin E) drugs that were removed from use in the past because of their neuro-and nephro-toxicity.17 An earlier study evaluated the efficacy of PB in MDR pathogens when there is very narrow choice.18 In case of A.
Colistin was removed in 2016 and the use of Fluoroquinolones has been cut by 91% in six years.
In addition, Novodiag CarbaR+ identifies a plasmid-mediated resistance to colistin. Colistin is considered the drug of last resort for many infections.